Last updated on August 2018

Safety and Exploratory Efficacy Study of NEUROSTEM Versus Placebo in Patients With Alzheimer's Disease

Brief description of study

This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM (human umbilical cord blood-derived mesenchymal stem cells) versus placebo via an Ommaya reservoir at 4 week intervals in patients with Alzheimer's disease.

Detailed Study Description

The study is divided into the 2 stages: dose-escalation in stage 1 and randomized and multiple-dose cohort parallel design in stage 2.The target population for enrollment in this study is patients with mild to moderate Alzheimer's disease.

Clinical Study Identifier: NCT02054208

Find a site near you

Start Over

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »